References

Albin RL, Greenamyre JT (1992). Alternative excitotoxic hypotheses. Neurology, 42: 733-738.

Bachurin S, Tkachenko S, Baskin I, Lermontova N, Mukhina T, Petrova L, Ustinov A, Proshin A, Grigoriev V, Lukoyanov N, Palyulin V, Zefirov N (2001). Neuroprotective and cognition-enhancing properties of MK-801 flexible analogs. Structure-activity relationships. Ann N Y Acad Sci, 939: 219-236.

Barnes CA, Danysz W, Parsons CG (1996). Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur. J. Neurosci., 8: 565-571.

Braak H, Braak E, Bohl J (1993). Staging of Alzheimer-related cortical destruction. Eur. Neurol., 33: 403-408.

Brorson JR, Bindokas VP, Iwama T, Marcuccilli CJ, Chisholm JC, Miller RJ (1995). The Ca²⁺ influx induced by β-amyloid peptide 25-35 in cultured hippocampal neurons results from network excitation. J. Neurobiol., 26: 325-338.

Clements JD, Lester RAJ, Tong G, Jahr CE, Westbrook GL (1992). The time course of glutamate in the synaptic cleft. Science, 258: 1498-1501.

Cullen WK, Wu JQ, Anwyl R, Rowan MJ (1996). β-amyloid produces a delayed NMDA receptor-dependent reduction in synaptic transmission in rat hippocampus. Neuroreport, 8: 87-92.

Danysz W, Parsons CG, Möbius HJ, Stöffler A, Quack G (2000). Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s disease – an unified glutamatergic hypothesis on the mechanism of action. Neurotox. Res., 2: 85-97.

Ferrarese C, Begni B, Canevari C, Zoia C, Piolti R, Frigo M, Appollonio I, Frattola L (2000). Glutamate uptake is decreased in platelets from Alzheimer’s disease patients. Ann. Neurol., 47: 641-643.

Francis PT, Sims NR, Procter AW, Bowen DM (1993). Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer’s disease – investigative and therapeutic perspectives. J. Neurochem., 60: 1589-1604.

Frankiewicz T, Parsons CG (1999). Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg²⁺ in hippocampal slices. Neuropharmacology, 38: 1253-1259.

Giulian D, Haverkamp LJ, Li J, Karshin WL, Yu J, Tom D, Li X, Kirkpatrick JB (1995). Senile plaques stimulate microglia to release a neurotoxin found in alzheimer brain. Neurochem. Int., 27: 119-137.

Greenamyre JT (1986). The role of glutamate in neurotransmission and in neurologic disease. Arch. Neurol., 43: 1058-1062.

Grilli M, Diodato E, Lozza G, Brusa R, Casarini M, Uberti D, Rozmahel R, Westaway D, St George-Hyslop P, Memo M, Ongini E (2000). Presenilin-1 regulates the neuronal threshold to excitotoxicity both physiologically and pathologically. Proc Natl Acad Sci USA, 97: 12822-12827.

Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP (1999). Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med, 5: 101-106.

Harris ME, Carney JM, Cole PS, Hensley K, Howard BJ, Martin L, Bummer P, Wang YN, Pedigo NW, Butterfield DA (1995). β-amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: implications for alzheimer’s disease. Neuroreport, 6: 1875-1879.

Harris ME, Wang YN, Pedigo NW, Hensley K, Butterfield DA, Carney JM (1996). Amyloid beta peptide (25-35) inhibits Na⁺-dependent glutamate uptake in rat hippocampal astrocyte cultures. J. Neurochem., 67: 277-286.

Hensley K, Carney JM, Stewart CA, Tabatabaie T, Pye Q, Floyd RA (1997). Nitrone-based free radical traps as neuroprotective agents in cerebral ischaemia and other pathologies. Int. rev. Neurobiol., 40: 299-317.

Ikonomovic MD, Mizukami K, Warde D, Sheffield R, Hamilton R, Wenthold RJ, Armstrong DM (1999). Distribution of glutamate receptor subunit NMDAR1 in the hippocampus of normal elderly and patients with Alzheimer’s disease. Exp. Neurol., 160: 194-204.

Klegeris A, McGeer PL (1997). β-amyloid protein enhances macrophage production of oxygen free radicals and glutamate. J. Neurosci. Res., 49: 229-235.

Koh JY, Yang LL, Cotman CW (1990). β-amyloid protein increases the vulnerability of cultured cortical neurones to excitotoxic damage. Brain Res., 315-320.

Kornhuber J, Mack-Burkhardt F, Riederer P, Hebenstreit GF, Reynolds GP, Andrews HB, Beckmann H (1989). [³H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J. Neural Transm., 77, 231-236.

Lees GJ (1993). Contributory mechanisms in the causation of neurodegenerative disorders. Neuroscience, 54: 287-322.

Li S, Mallory M, Alford M, Tanaka S, Masliah E (1997). Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J. Neuropathol. Exp. Neurol., 56: 901-911.

Lipton SA, Rosenberg PA (1994). Excitatory amin acids as a final common pathway for neurologic disorders. N. Engl. J. Med., 330: 613-622.

Lukoyanov NV, Paula-Barbosa MM (2001). Memantine, but not dizocilpine, ameliorates cognitive deficits in adult rats withdrawn from chronic ingestion of alcohol. Neurosci. Lett., 309: 45-48.

Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L (1996). Deficient glutamate transport is associated with neurodegeneration in Alzheimer’s disease. Ann. Neurol., 40: 759-766.

Masliah E, Mallory M, Alford M, Tanaka S, Hansen LA (1998). Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease. J. Neuropathol. Exp. Neurol., 57: 1041-1052.

Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE (1992). β-Amyloid Peptides Destabilize Calcium Homeostasis and Render Human Cortical Neurons Vulnerable to Excitotoxicity. J. Neurosci., 12: 376-389.

Mattson MP, Zhu H, Yu J, Kindy MS (2000). Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: involvement of perturbed calcium homeostasis. J. Neurosci., 20: 1358-1364.

Miguel-Hidalgo JJ, Alvarez XA, Quack G, Cacabelos R (1998). Protection by memantine against Aβ(1-40)-induced neurodegeneration in Ca1 subfield. Neurobiol. Aging, 19: 542.

Misztal M, Frankiewicz T, Parsons CG, Danysz W (1996). Learning deficits induced by chronic intraventricular infusion of quinolinic acid – protection by MK-801 and memantine. Eur. J. Pharmacol., 296: 1-8.

Moechars D, Dewachter I, Lorent K, Reversé D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F (1999). Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem., 274: 6483-6492.

Moechars D, Lorent K, De Strooper B, Dewachter I, Van Leuven F (1996). Expression in brain of amyloid precursor protein mutated in the α-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J., 15: 1265-1274.

Noda M, Nakanishi H, Akaike N (1999). Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide. Neuroscience, 92: 1465-1474.

Parsons CG, Danysz W, Quack G (1999). Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist – a review of preclinical data. Neuropharmacology, 38, 735-767.

Parsons CG, Gruner R, Rozental J, Millar J, Lodge D (1993). Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology, 32: 1337-1350.

Pearson RC, Esiri MM, Hiorns RW, Wilcock GK, Powell TP (1985). Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci USA, 82: 4531-4534.

Reisberg B (2000). Memantine in moderately severe to severe Alzheimer’s disease (AD): results of a placebo-controlled 6-month trial. Neurobiol. Aging, 21: 275.

Rogers J, Morrison JH (1985). Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer’s disease. J. Neurosci., 5: 2801-2808.

Schneider I, Reverse D, Dewachter I, Ris L, Caluwaerts N, Kuiperi C, Gilis M, Geerts H, Kretzschmar H, Godaux E, Moechars D, Van Leuven F, Herms J (2001). Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. J. Biol. Chem., 276: 11539-11544.

Stieg PE, Sathi S, Warach S, Le DA, Lipton SA (1999). Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. Eur. J. Pharmacol., 375: 115-20.

Wenk GL, Danysz W, Mobley SL (1994). Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Res., 655: 7-11.

Wenk GL, Danysz W, Mobley SL (1995). MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur. J. Pharmac. Env. Tox. Pharmacol., 293: 267-270.

Wenk GL, Danysz W, Roice DD (1996). The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. Neuroreport, 7: 1453-1456.

Willard LB, Hauss-Wegrzyniak B, Danysz W, Wenk GL (2000). The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp. Brain Res., 134: 58-65.

Winblad B, Poritis N (1998). Clinical improvement in a placebo-controlled trial with memantine in care-dependent patients with severe dementia. Neurobiol. Aging, 19: S303.

Zajaczkowski W, Frankiewicz T, Parsons CG, Danysz W (1997). Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology, 36: 961-971.

Zajaczkowski W, Quack G, Danysz W (1996). Infusion of (+)-MK-801 and memantine – contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur. J. Pharmacol., 296: 239-246.